Skip to main content
Enlivex Therapeutics Ltd. logo

Enlivex Therapeutics Ltd. — Investor Relations & Filings

Ticker · ENLV ISIN · USM201561018 US Manufacturing
Open in API
Filings indexed 379 across all filing types
Latest filing 2015-06-22 Regulatory Filings
Country US United States of America
Listing US ENLV

About Enlivex Therapeutics Ltd.

https://www.enlivex.com/

Enlivex Therapeutics Ltd. is a clinical-stage company developing macrophage reprogramming immunotherapy. Its primary focus is the development of Allocetra™, a universal, off-the-shelf cell therapy designed to rebalance immune hyper-responses. The therapy aims to modulate macrophages as a therapeutic strategy against inflammatory diseases. Enlivex is evaluating Allocetra™ for multiple indications, including acute inflammatory conditions like sepsis and chronic inflammatory diseases such as osteoarthritis. The product offers flexible administration options, including systemic intravenous infusion and targeted local injections, and has been administered in clinical trials to over 250 patients with no reported drug-related serious adverse events.

Recent filings

Filing Released Lang Actions
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing, which is a report of a foreign private issuer submitted to the SEC. It contains a press release announcing preclinical proof-of-concept results related to the company's read-through platform in Spinal Muscular Atrophy. The document is short (2301 characters) and primarily serves to provide an update or announcement rather than detailed financial data or comprehensive reporting. It does not contain full financial statements or detailed analysis typical of annual or interim reports. It also does not fit into categories like earnings release, management reports, or governance information. Given the nature of Form 6-K filings as periodic updates and announcements by foreign private issuers, and the document's content being a press release announcement, the best fitting category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous regulatory announcements that do not fit other specific categories.
2015-06-22 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing, which is a report of a foreign private issuer submitted to the SEC. It contains a press release announcing the start of a Phase 3 study for a drug, but does not include detailed financial statements or substantive financial data. The document length is short (2345 characters) and it primarily serves as an announcement rather than a full report. It does not fit into categories like Annual Report, Interim Report, or Earnings Release. It is also not a certification or insider dealing report. Given these factors, the document is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2015-06-15 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, Bio Blast Pharma Ltd., with the SEC. It contains a press release announcing financial results for the first quarter ended March 31, 2015. The document length is 2258 characters, which is relatively short and primarily serves as an announcement of the financial results rather than the full report itself. The text states that the press release is attached as Exhibit 99.1 and incorporated by reference, indicating this filing is a report of the financial results announcement rather than the full interim or quarterly report. Form 6-K filings typically serve as regulatory filings for foreign issuers to report material information. Therefore, this document fits best under Regulatory Filings (RNS) as it is a regulatory announcement of financial results, not the full interim report or earnings release.
2015-05-19 English
FORM 6-K
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, Bio Blast Pharma Ltd., reporting the results of the Annual General Meeting (AGM) held on May 5, 2015. The text explicitly states 'Results of the Annual General Meeting of Shareholders' and mentions approval of agenda items. The document is short (1976 characters) and primarily announces the AGM results rather than providing detailed AGM materials or presentations. According to the filing definitions, announcements of voting results at general meetings fall under 'Declaration of Voting Results & Voting Rights Announcements' (DVA). Therefore, this document is best classified as DVA rather than AGM Information or other categories.
2015-05-05 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, BioBlast Pharma Ltd., with the SEC. It contains a press release announcing that the FDA granted Fast Track designation to a drug candidate. The document is short (2153 characters) and primarily serves as a regulatory announcement of this event. It does not contain financial statements, detailed financial data, or comprehensive reports. It is not an annual or quarterly report, nor an earnings release or management discussion. The document is a regulatory filing reporting a material event by the company. Therefore, the appropriate classification is Regulatory Filings (RNS).
2015-04-09 English
FORM 6-K
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a Form 6-K filed by Bio Blast Pharma Ltd., which includes a Notice of Meeting, Proxy Statement, and Proxy Card for the Annual General Meeting (AGM) scheduled for May 5, 2015. The text explicitly states that the Notice of Meeting and Proxy Statement are attached as Exhibit 99.1 and incorporated by reference. The document is short (2442 characters) and primarily serves to announce and provide proxy materials for the AGM, rather than presenting the AGM materials themselves or the full report. According to the classification rules, proxy materials and notices related to shareholder meetings fall under Proxy Solicitation & Information Statement (PSI). The document is not the AGM presentation itself (AGM-R), nor is it an announcement of a report publication (RPA). Therefore, the best fit is PSI.
2015-03-31 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.